West Pharmaceutical Services Inc. (NYSE:WST) issued an update on its FY16 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $2.15-2.25 for the period, compared to the Thomson Reuters consensus estimate of $2.22.
West Pharmaceutical Services Inc. (NYSE:WST) opened at 74.76 on Thursday. The firm has a market cap of $5.47 billion, a price-to-earnings ratio of 54.45 and a beta of 0.87. West Pharmaceutical Services Inc. has a 52-week low of $52.79 and a 52-week high of $84.33. The company has a 50 day moving average price of $80.26 and a 200-day moving average price of $75.18.
West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, July 28th. The company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.03. The company earned $388 million during the quarter, compared to the consensus estimate of $384.58 million. West Pharmaceutical Services had a return on equity of 14.40% and a net margin of 6.99%. The firm’s quarterly revenue was up 7.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.47 earnings per share. Equities research analysts anticipate that West Pharmaceutical Services Inc. will post $2.22 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, November 2nd. Stockholders of record on Wednesday, October 19th will be given a dividend of $0.13 per share. This represents a $0.52 dividend on an annualized basis and a dividend yield of 0.70%. This is an increase from West Pharmaceutical Services’s previous quarterly dividend of $0.12. West Pharmaceutical Services’s payout ratio is presently 35.04%.
A number of research firms recently commented on WST. Zacks Investment Research downgraded West Pharmaceutical Services from a hold rating to a sell rating in a report on Wednesday. Jefferies Group reiterated a hold rating on shares of West Pharmaceutical Services in a report on Thursday, August 4th. Wells Fargo & Co. downgraded West Pharmaceutical Services from an outperform rating to a market perform rating in a report on Wednesday, September 21st. Finally, Janney Montgomery Scott reiterated a fair value rating and issued a $72.55 price objective (down previously from $90.00) on shares of West Pharmaceutical Services in a report on Monday.
In other West Pharmaceutical Services news, SVP Karen Flynn sold 14,581 shares of the stock in a transaction dated Tuesday, September 6th. The stock was sold at an average price of $83.28, for a total value of $1,214,305.68. Following the completion of the sale, the senior vice president now directly owns 13,513 shares in the company, valued at $1,125,362.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Paula A. Johnson sold 3,042 shares of the stock in a transaction dated Tuesday, August 23rd. The stock was sold at an average price of $81.55, for a total value of $248,075.10. Following the completion of the sale, the director now owns 38,450 shares of the company’s stock, valued at $3,135,597.50. The disclosure for this sale can be found here. 5.13% of the stock is owned by company insiders.
Large investors have recently made changes to their positions in the company. BlackRock Japan Co. Ltd acquired a new stake in shares of West Pharmaceutical Services during the second quarter valued at about $151,000. Seven Eight Capital LLC increased its stake in shares of West Pharmaceutical Services by 5,481.4% in the second quarter. Seven Eight Capital LLC now owns 2,400 shares of the company’s stock valued at $182,000 after buying an additional 2,357 shares during the period. Advisor Group Inc. acquired a new stake in shares of West Pharmaceutical Services during the second quarter valued at about $281,000. Highbridge Capital Management LLC acquired a new stake in shares of West Pharmaceutical Services during the second quarter valued at about $291,000. Finally, Trexquant Investment LP acquired a new stake in shares of West Pharmaceutical Services during the second quarter valued at about $310,000. Institutional investors own 90.24% of the company’s stock.
About West Pharmaceutical Services
West Pharmaceutical Services, Inc (West) is a manufacturer of components and systems for the packaging and delivery of injectable drugs, as well as delivery system components for the pharmaceutical, healthcare and consumer products industries. The Company’s segments include Pharmaceutical Packaging Systems segment (Packaging Systems) and the Pharmaceutical Delivery Systems segment (Delivery Systems).
Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with MarketBeat.com's FREE daily email newsletter.